Does the upstaging of breast cancer based on grade and hormone receptor status in AJCC 8 change your treatment recommendations?

The new stage should not in and of itself change management as the data and studies remain unchanged. Thus, for triple negative cancers, I would continue to hypofractionate if intending to treat the breast alone. In cases where I would consider RNI based on the available data (MA20 and EORTC 22922),...